valu usd unless otherwis note
soliri see major win nmo potenti
upsid market breadth
view nmo data come rel unexpect upsid ad
anoth potenti larg market growth opportun soliri
sh pt soliri expans help skeptic pipelin
product structur continu see one large-cap
compani highest growth potenti
posit result nmo win soliri true market
opportun remain key focu nmo indic morn
announc impress posit data prevent trial
soliri neuromyel optica spectrum disord nmosd data
highli impress differ vs placebo
primari endpoint time first on-trial relaps soliri show
durabl relaps prevent soliri treat patient
remain relaps free vs placebo patient updat add
anoth potenti larg rare diseas market opportun soliri
estim elig nmo patient us vs model
refractori patient potenti approv
depend regulatori filing/evalu timelin soliri data appear
highli compel suggest signific upsid vs model base
broader util focu payor signal if/how access
may limit price concern increas pt
probabl probabl model peak
global soliri nmosd given anticip rel restrict
use set
market opportun model updat call manag
detail market opportun soliri nmosd view
prevalence-ori commerci plan nmo prevalence/
lack approv
therapeut though estim diagnos popul
us similar biomark
posit half like elig prevent
trial could present upsid model estim
elig patient prior steroid immunosuppress rituxumab
us/eu model inhibitor achiev us/eu peak share
model peak global soliri nmo sale
peak complement franchis sale soliri
indic rais soliri probabl success
nmosd ad pt
price prior trade day market close estimate unless otherwis note
bloomberg capit market estim upside/downside/target
rate outperform pt base
sum-of-the-part sotp methodolog estim
probability-adjust npv follow soliri sale pnh
soliri sale ahu strensiq
sale kanuma sale lal-d
soliri sale mg soliri sale nmo
compani project
cash posit compani debt posit
price target support outperform rate
upsid scenario assum faster-than-
expect uptak metabol franchis
regulatori approv pnh clinic success
trial ahu
downsid scenario assum
approv pnh addit neg readout ahu
mg nmosd addit assum discount
soliri npv base earlier-than-anticip biosimilar
entri case expect stock trade base
valu discount soliri busi metabol
despit pnh patient competit like soliri
mg approv see declin soliri pnh sale
larg off-set expans ahu mg focu
long-term revenu expens guidanc amid intens
development competit field complement
inhibitor anticip restructur could help remov
near-term overhang stock follow manag
could help protect pnh ahu market
competitor see dose regimen
promis highli conveni though riski development
strategi present pk dose
use remain unclear whether
recycl strategi use extend half life
hold high concentr note therapeut
antibodi commerci high dose
though conced dose would like seen
conveni mani competitor develop daily/
ip extens like fend soliri biosimilar
see recent composit matter formul
method use patent extend ip us
hold launch biosimilar anticip issuanc
similar patent eu extend protect
eu countri view biosimilar soliri near-term
upcom potenti catalyst initi
subq studi result
ahu studi adult pediatr pt pdufa
pnh feb eu approv
pnh mid regulatori file soliri nmosd
risk factor neg influenc valuat
rate includ develop setback includ
regulatori reject pnh neg readout
studi ahu posit develop progress
safeti extens studi on-going patient complet prevent trial experienc
relaps trial elig enrol open-label long-term extens studi
soliri origin patient primari efficaci analysi enrol
safeti extens plan present interim safeti data extens arm
next year addit includ data third patient plan
registr file encouragingli patient complet prevent studi elect
continu extens studi expect major surpris given
substanti safeti dataset alreadi establish soliri clinic develop
well real world set
rate outperform pt base sum-of-the-part sotp
methodolog estim probability-adjust npv follow soliri sale pnh
soliri sale ahu strensiq sale
kanuma sale lal-d soliri sale mg soliri sale nmo
compani project cash posit
compani debt posit price target support outperform rate
risk rate price target
factor neg influenc valuat rate includ develop
set-back includ neg readout studi ahu posit develop
progress competitor complement program
alexion pharmaceut global fulli integr biopharmaceut compani
focus treatment rare diseas lead commerci product soliri eculizumab
human monoclon antibodi direct complement factor soliri approv
treatment paroxysm nocturn hemoglobinuria pnh atyp hemolyt urem
syndrom ahu gener myasthenia gravi three ultra-rar diseas caus
uncontrol complement activ alexion aim expand soliri neurolog
transplant disord conduct late-stag develop program neuromyel optica
nmo delay graft function dgf antibody-medi reject amr
alexion also market strensiq asfotas alfa enzym replac therapi ert indic
hypophosphatasia grant us approv octob eu approv
septemb approv japan juli addit
acquisit synageva alexion own kanuma sebelipas alfa ert treatment
lysosom acid lipas defici lal-d receiv eu us market approv
septemb decemb respect approv japan march
compani current develop next gener complement inhibitor
treatment pnh ahu potenti complement associ diseas
compani report capit market estim
chang model revenu expens expens expens incom incom expens incom incom non- non- exhibit incom statement
compani report capit market estim
compani report capit market estim
soliri pnh ahu lal-d mg nmo pnh ahu mg nmo valu stock dilut share outstand net market sum-of-the-part valuat
